Beyond Clinical Trials: Perampanel across the Lifespan in Contemporary Epilepsy Practice
Journal of Experimental Neurology · 21.08.2026 · 7 (3) · 101
DOI: 10.33696/neurol.7.134 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Neurology, online erschienen am 21.08.2026. Verfasst von Anita N. Datta.
Abstract (Originalsprache)
Perampanel (PER) occupies a singular place in anti-seizure pharmacology. As the only anti-seizure medication (ASM) that acts through selective, non-competitive blockade of ?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, the principal mediators of fast excitatory neurotransmission in the brain.
Zitieren
APA
Datta, A. N. (2026). Beyond Clinical Trials: Perampanel across the Lifespan in Contemporary Epilepsy Practice. Journal of Experimental Neurology, 7(3), 101. https://doi.org/10.33696/neurol.7.134
Vancouver
Datta AN. Beyond Clinical Trials: Perampanel across the Lifespan in Contemporary Epilepsy Practice. Journal of Experimental Neurology. 2026;7(3):101. doi:10.33696/neurol.7.134
BibTeX
@article{Datta2026,
author = {Datta, Anita N.},
title = {Beyond Clinical Trials: Perampanel across the Lifespan in Contemporary Epilepsy Practice},
journal = {Journal of Experimental Neurology},
year = {2026},
volume = {7},
number = {3},
pages = {101},
doi = {10.33696/neurol.7.134}
}
EUVIMED